Reimbursement
& Go-To-Market in France
Medical Device, Medtech Equipment, E-Health Solution
Hospital dispensing & automation
Enhancing your reimbursement strategy
Generating early access among reference centers and Kols
Building-up a community of early adopters
Guiding and supporting for the commercial scale-up (direct or non direct)
The reasons why Caredis
Reimbursement @ Go To Market: the market entry in France for an innovative medical device, a breakthtough medical technology or a disruptive e-health solution meets two challenging crossroads :
- What is the fastest pathway to get a safe reimbursement with a premium price at the country level ?
- What is the roadmap of early commercial steps to enhance reimbursement and to scale-up as of the obtention of reimbursement ?
If you have no/low presence in France to design the plans answering these questions and to execute them in due time, Caredis can help you to make them happened.
At this stage of business, you need a seasoned partner who plays by your corporate and local books not only to facilitate the design of the plan but also to deliver by interacting with healthcare professionals.
You need this partner part-time by deciding the magnitude of his efforts, targets, time to grow your footprint. It’s taylor made based on your budget and your business planning.
These professional services always remain more cost effective than hiring a local full time person.
The Go-To-Market strategy in France: What is the fastest pathway to get a safe reimbursement with a premium price at the country level ?
- The very first step is to identify the best pathway to get access to reimbursement. It is often a mix of assessing the clinical dossier of existing and ongoing clinical outcomes from trials and the current status of existing solutions and competitors.
- Then there are often several potential pathways to reach reimbursement set up by healthcare authoritsites rto foster innovative trataments/solutions.
- One of the criteria of choice for an pathway versu another depends on the expectations of the selling price. A premium price requests a robust clinical package often supported by randomized controled trials. In some specific cases, pathways supporting early access can facilitate the funding of trials.
The go-to-market strategy in France: What is the roadmap of early commercial steps to enhance reimbursement and to scale-up as of the obtention of reimbursement ?
- The go-to-market strategy should be aligned with the market access strategy. However robust the clinical dossier is for the reimbursement, it is highly recommended to build-up a small community of early users willing to speak up during the filling process if needed. Initiating partnerhsip with few reference center is always helpful to raise awareness among the medical community.
- These early footprint enables to execute a commercial prelaunch to assess the effort of educating the market and identify the key milestones and the commercial set up
- The commercial scale-up requests to design the optimal commercial organization by building-up its own commercial team or by dealing with a local partner. As a key European market, France is more a « direct » country than a country driven by distributors.
Partners
